Fifth Third Bancorp Raises Position in Catalyst Pharmaceuticals, Inc. $CPRX

Fifth Third Bancorp grew its holdings in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 4,708.1% in the first quarter, HoldingsChannel reports. The fund owned 28,368 shares of the biopharmaceutical company’s stock after purchasing an additional 27,778 shares during the quarter. Fifth Third Bancorp’s holdings in Catalyst Pharmaceuticals were worth $702,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also recently modified their holdings of CPRX. WINTON GROUP Ltd increased its position in Catalyst Pharmaceuticals by 546.7% in the fourth quarter. WINTON GROUP Ltd now owns 353,529 shares of the biopharmaceutical company’s stock worth $8,251,000 after buying an additional 298,862 shares in the last quarter. Merit Financial Group LLC purchased a new position in shares of Catalyst Pharmaceuticals during the 4th quarter valued at about $654,000. Wakefield Asset Management LLLP purchased a new position in shares of Catalyst Pharmaceuticals during the 4th quarter valued at about $1,203,000. Universal Beteiligungs und Servicegesellschaft mbH grew its stake in shares of Catalyst Pharmaceuticals by 30.0% during the 4th quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 167,763 shares of the biopharmaceutical company’s stock valued at $3,913,000 after acquiring an additional 38,695 shares during the period. Finally, Stratos Wealth Advisors LLC grew its stake in shares of Catalyst Pharmaceuticals by 21.2% during the 4th quarter. Stratos Wealth Advisors LLC now owns 117,721 shares of the biopharmaceutical company’s stock valued at $2,748,000 after acquiring an additional 20,628 shares during the period. 79.22% of the stock is currently owned by hedge funds and other institutional investors.

Catalyst Pharmaceuticals Stock Performance

NASDAQ CPRX opened at $31.49 on Tuesday. Catalyst Pharmaceuticals, Inc. has a 12 month low of $19.05 and a 12 month high of $32.56. The stock has a market cap of $3.86 billion, a PE ratio of 18.10, a P/E/G ratio of 0.96 and a beta of 0.74. The stock’s 50 day moving average is $31.39 and its 200 day moving average is $27.39.

Analyst Upgrades and Downgrades

CPRX has been the topic of a number of recent analyst reports. Zacks Research cut shares of Catalyst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Monday, May 18th. Weiss Ratings upgraded shares of Catalyst Pharmaceuticals from a “buy (b-)” rating to a “buy (b)” rating in a research report on Wednesday, June 3rd. Wall Street Zen cut shares of Catalyst Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, May 9th. HC Wainwright downgraded shares of Catalyst Pharmaceuticals from a “buy” rating to a “neutral” rating and decreased their price objective for the company from $35.00 to $31.50 in a research report on Thursday, May 28th. Finally, Stephens set a $32.00 target price on shares of Catalyst Pharmaceuticals in a research note on Thursday, May 7th. Two equities research analysts have rated the stock with a Strong Buy rating, one has given a Buy rating and six have given a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $32.00.

Catalyst Pharmaceuticals Profile

Catalyst Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for patients living with rare neuromuscular, neurological and metabolic diseases. The company’s mission centers on delivering safe and effective treatments that address unmet medical needs in small patient populations.

The company’s lead product is Firdapse® (amifampridine phosphate), a treatment approved by the U.S. Food and Drug Administration for adults with Lambert-Eaton Myasthenic Syndrome (LEMS).